A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs PTI 428 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Proteostasis Therapeutics
- 15 Apr 2019 Status changed from recruiting to completed.
- 12 Nov 2018 Planned End Date changed from 1 Mar 2019 to 1 Feb 2019.
- 12 Nov 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Feb 2019.